OMI vs DBVT vs MCK vs ALKS

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -74. 2% for Owens & Minor, Inc. (OMI). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus McKesson Corporation at 29. 2x. On forward P/E, Owens & Minor, Inc. is actually cheaper at 2. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -93. 5% for Owens & Minor, Inc. (OMI). Over 10 years, the gap is even starker: MCK returned +348. 1% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Owens & Minor, Inc. 's 1. 44β — meaning OMI is approximately 3251% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -74. 2% for Owens & Minor, Inc. (OMI). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -39. 8% for Owens & Minor, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Owens & Minor, Inc.

(OMI) trades at 2. 3x forward P/E versus 19. 3x for McKesson Corporation — 17. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, MCK (0.

4% yield) pays a dividend. OMI, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, OMI: -86. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OMI is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; MCK is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.